Wada, Shuhei
Iwamoto, Kunihiro
Okumura, Hiroki
Hida, Hirotake
Hiraoka, Shuichi
Kamei, Aya
Mori, Daisuke
Yamada, Kiyofumi
Ozaki, Norio
Funding for this research was provided by:
Meiji Seika Pharma Co
Article History
Received: 18 December 2022
Accepted: 7 March 2023
First Online: 14 March 2023
Declarations
:
: Ethics approval was obtained from the Nagoya University Clinical Research Review Board (Protocol No.: CRB41800040). Written informed consent will be obtained from all study participants.
: Written consent will be obtained from all study participants.
: SW has no conflicts of interest to declare. KI has received speakers’ honoraria from Eisai, Kyowa, Meiji Seika Pharma, MSD, Otsuka, Sumitomo Dainippon, Taisho, Takeda, Towa, and Viatris. HO has no conflicts of interest to declare. HH has no conflicts of interest to declare. SH and AK are full-time employees of Meiji Seika Pharma Co., Ltd. DM has no conflicts of interest to declare. KY has received research support or speakers’ honoraria from Sumitomo Dainippon, Otsuka, Eisai, and DAIICHI SANKYO. NO has received research support or speakers’ honoraria from, or has served as a consultant to, Sumitomo Dainippon, Eisai, Otsuka, KAITEKI, Mitsubishi Tanabe, Shionogi, Eli Lilly, Mochida, DAIICHI SANKYO, Nihon Medi-Physics, Takeda, Meiji Seika Pharma, EA Pharma, Pfizer, MSD, Lundbeck Japan, Taisho Pharma, Janssen, UCB, Shionogi, Nihon Medi-Physics, Tsumura, Novartis, and Astellas.